In addition, anti-tumor efficacy was also observed in mouse tumors models following peritumoral treatment with an anti-Clec9a nanobody engineered to target an IFN mutein to cDC1s (25), suggesting IFN signaling in cDC1s is both necessary and sufficient and, notably, that delivery of a DC-targeted IFN holds promise as a cancer immunotherapy. Here, CLEC9A is linked to neoplasm.